Yuanyuan Tu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuanyuan Tu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Manhui Zhu
Department of Ophthalmology, Lixiang Eye Hospital of Soochow University
3 shared publications - Desheng Cao
Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China
1 shared publication - E. Song
Department of Ophthalmology, Lixiang Eye Hospital of Soochow University
1 shared publication Jia Zeng
Department of Ophthalmology, Lixiang Eye Hospital of Soochow University, Suzhou 215002, China
1 shared publication- Junliang Zhu
Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China
1 shared publication Kai Leng
Department of Medical Informatics, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadj0006
Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice
As an important modality for choroidal neovascularization (CNV) treatment, intravitreal injection of vascular endothelial growth factor A (VEGFA) inhibitors suffers from undesired response rate, low patient compliance, and ocular damage. Here, dynamically covalent lipid nanoparticles (LNPs) were engineered to mediate VEGFA gene editing and CNV treatment by codelivering Cas9 mRNA (mCas9) and single guide RNA (sgRNA) targeting VEGFA (sgVEGFA). A library of lipidoids bearing iminoboronate ester linkage was developed via facile “one-pot” synthesis, and the top-performing lipidoid-A 4 B 3 C 7 was formulated into LNP-A 4 B 3 C 7 with the highest mRNA transfection efficiency. Inside the diseased retinal pigment epithelial cells, LNPs were dissociated upon H 2 O 2 -triggered lipidoid degradation, facilitating mRNA/sgRNA release to potentiate the gene editing efficiency. In laser-induced CNV mice, mCas9/sgVEGFA@LNP-A 4 B 3 C 7 after single intravitreal injection led to pronounced VEGFA disruption and CNV area reduction, outperforming the clinical anti-VEGF drug in eliciting sustained therapeutic effect. This study establishes a robust nonviral platform for mRNA delivery and genome editing and renders a promising strategy for CNV treatment.
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadj0006
Top Cited PapersOpen AccessDynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice
As an important modality for choroidal neovascularization (CNV) treatment, intravitreal injection of vascular endothelial growth factor A (VEGFA) inhibitors suffers from undesired response rate, low patient compliance, and ocular damage. Here, dynamically covalent lipid nanoparticles (LNPs) were engineered to mediate VEGFA gene editing and CNV treatment by codelivering Cas9 mRNA (mCas9) and single guide RNA (sgRNA) targeting VEGFA (sgVEGFA). A library of lipidoids bearing iminoboronate ester linkage was developed via facile “one-pot” synthesis, and the top-performing lipidoid-A 4 B 3 C 7 was formulated into LNP-A 4 B 3 C 7 with the highest mRNA transfection efficiency. Inside the diseased retinal pigment epithelial cells, LNPs were dissociated upon H 2 O 2 -triggered lipidoid degradation, facilitating mRNA/sgRNA release to potentiate the gene editing efficiency. In laser-induced CNV mice, mCas9/sgVEGFA@LNP-A 4 B 3 C 7 after single intravitreal injection led to pronounced VEGFA disruption and CNV area reduction, outperforming the clinical anti-VEGF drug in eliciting sustained therapeutic effect. This study establishes a robust nonviral platform for mRNA delivery and genome editing and renders a promising strategy for CNV treatment.
- Open Access
Role of macrophage in ocular neovascularization
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Geniposide Attenuates Hyperglycemia‐Induced Oxidative Stress and Inflammation by Activating the Nrf2 Signaling Pathway in Experimental Diabetic Retinopathy
Geniposide (GEN) is a natural antioxidant and anti‐inflammatory product and plays an important role in the treatment of diabetes and diabetic complications. To explore the biological functions and mechanism of GEN in diabetic retinopathy (DR), we constructed the in vitro and in vivo model of DR by using primary cultured mouse retinal Müller cells and C57BL/6 mice, respectively. We found that GEN inhibited ROS accumulation, NF‐κB activation, Müller cell activation, and inflammatory cytokine secretion both in vitro and in vivo, which is probably mediated through the Nrf2 pathway. Exendin (9‐39) (EX‐9), an antagonist of glucagon‐like peptide‐1 receptor (GLP‐1R), abolished the protective effect of GEN on high glucose‐ (HG‐) induced Müller cells. Additionally, GEN decreased hyperglycemia‐induced damage to Müller cells and blood‐retinal barrier in the retinas of mice with DR. We demonstrated that GEN was capable of protecting Müller cells and mice from HG‐induced oxidative stress and inflammation, which is mostly dependent on the Nrf2 signaling pathway through GLP‐1R. GEN may be an effective approach for the treatment of DR.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessGeniposide Attenuates Hyperglycemia‐Induced Oxidative Stress and Inflammation by Activating the Nrf2 Signaling Pathway in Experimental Diabetic Retinopathy
Geniposide (GEN) is a natural antioxidant and anti‐inflammatory product and plays an important role in the treatment of diabetes and diabetic complications. To explore the biological functions and mechanism of GEN in diabetic retinopathy (DR), we constructed the in vitro and in vivo model of DR by using primary cultured mouse retinal Müller cells and C57BL/6 mice, respectively. We found that GEN inhibited ROS accumulation, NF‐κB activation, Müller cell activation, and inflammatory cytokine secretion both in vitro and in vivo, which is probably mediated through the Nrf2 pathway. Exendin (9‐39) (EX‐9), an antagonist of glucagon‐like peptide‐1 receptor (GLP‐1R), abolished the protective effect of GEN on high glucose‐ (HG‐) induced Müller cells. Additionally, GEN decreased hyperglycemia‐induced damage to Müller cells and blood‐retinal barrier in the retinas of mice with DR. We demonstrated that GEN was capable of protecting Müller cells and mice from HG‐induced oxidative stress and inflammation, which is mostly dependent on the Nrf2 signaling pathway through GLP‐1R. GEN may be an effective approach for the treatment of DR.